Thu, Jul 10, 2014, 12:06 AM EDT - U.S. Markets open in 9 hrs 24 mins


% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • loriskhireward loriskhireward Nov 14, 2011 1:10 PM Flag

    How long 'til Dificid is first-line?

    "The incidence and severity of CDAD has increased dramatically in the U.S. in the past decade and is continuing to rise each year," Sherwood Gorbach, MD, the company's chief scientific officer, says in a news release. "Dificid is an important new first-line treatment option for patients who may be most at risk of disease recurrence, for whom producing a sustained clinical response is critical."

    NOTE to "doc" - just who do you think they're talking about here? who would be most "at-risk" of recurrence? to hear your argument, it'd be anyone who is hospitalized - y'know, they're not washing their hands enough...AND, those would be the more "vulnerable" seniors? i believe so.

    "CDAD is a serious illness that can be incredibly disruptive to patients' lives, sometimes causing as many as 20 or more episodes of diarrhea a day which in certain patients can result in significant dehydration," Kathleen Mullane, DO, of the University of Chicago, says in the news release.

    NOTE to "doc" - do we want a drug with better cure rate than "slurpie"? you tell me...20 episodes DAILY!?!?!? and you want to use an inferior treatment?!?!?

    Cost of Treating C. Diff

    The news release says medical treatment and hospital stays associated with C. diff cost the U.S. health care system as much as $3.8 billion a year.

    NOTE to "doc" - I would argue that most of this cost is hospitalization & RE-HOSPITALIZATIONS...surely not the $1/dose you always rant about...your explanation?

    Also, the company says a recent survey of the incidence and severity of C. diff in U.S. hospitals found that C. diff patients had lengths of hospital stay nearly three times longer than average, with mortality rates more than four times higher than for the average person who is hospitalized.

    NOTE to "doc" - please study the 40-day clinical data...please study it...pretty please.

    The FDA says the safety and efficacy of Dificid were shown in two trials that included 564 patients with C. diff that compared effectiveness of the drug with patients taking vancomycin, an antibiotic. In the trials, more patients treated with Dificid were considered CURED (my emphasis) after three weeks of treatment (stay with me, "doc", longer hospital stays mentioned above), compared with people taking vancomycin, the FDA says.

    evidence is mounting, "doc"...please research the data before posting.

    I am putting forth many opinions, none of which are medical, but many of which are LOGICAL/PRACTICAL...correct, "doc"?

12.780.00(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.